0.5925
price down icon6.01%   -0.0379
after-market Handel nachbörslich: .62 0.0275 +4.64%
loading
Schlusskurs vom Vortag:
$0.6304
Offen:
$0.5967
24-Stunden-Volumen:
1.38M
Relative Volume:
1.06
Marktkapitalisierung:
$49.64M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-0.3329
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
-19.93%
1M Leistung:
-58.71%
6M Leistung:
-83.22%
1J Leistung:
-88.36%
1-Tages-Spanne:
Value
$0.5633
$0.6279
1-Wochen-Bereich:
Value
$0.5633
$0.76
52-Wochen-Spanne:
Value
$0.5633
$5.275

Sutro Biopharma Inc Stock (STRO) Company Profile

Name
Firmenname
Sutro Biopharma Inc
Name
Telefon
650-392-8412
Name
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
0
Name
Twitter
@SutroBio
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
STRO's Discussions on Twitter

Vergleichen Sie STRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
STRO
Sutro Biopharma Inc
0.5925 49.64M 153.73M -106.79M -115.93M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-17 Herabstufung H.C. Wainwright Buy → Neutral
2025-03-14 Herabstufung BofA Securities Buy → Underperform
2025-03-14 Herabstufung Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 Herabstufung Wedbush Outperform → Neutral
2024-05-08 Eingeleitet BofA Securities Buy
2023-11-09 Eingeleitet Deutsche Bank Buy
2023-10-06 Eingeleitet Oppenheimer Outperform
2023-03-21 Herabstufung Wells Fargo Overweight → Equal Weight
2022-08-18 Fortgesetzt Wells Fargo Overweight
2021-06-18 Eingeleitet H.C. Wainwright Buy
2020-12-03 Eingeleitet Stifel Buy
2020-09-02 Eingeleitet Jefferies Buy
2020-07-16 Eingeleitet Wells Fargo Overweight
2020-01-13 Eingeleitet SunTrust Buy
2019-10-07 Eingeleitet BTIG Research Buy
2019-07-18 Eingeleitet Deutsche Bank Buy
2019-04-29 Eingeleitet H.C. Wainwright Buy
2018-10-22 Eingeleitet JMP Securities Mkt Outperform
2018-10-22 Eingeleitet Piper Jaffray Overweight
2018-10-22 Eingeleitet Wedbush Outperform
Alle ansehen

Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten

pulisher
10:21 AM

Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges - Investing.com India

10:21 AM
pulisher
Apr 02, 2025

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Hold” from Analysts - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 25, 2025

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 23, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World

Mar 23, 2025
pulisher
Mar 20, 2025

Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Biotech company based in Peninsula laying off 90% of staff - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle

Mar 19, 2025
pulisher
Mar 19, 2025

The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media

Mar 19, 2025
pulisher
Mar 18, 2025

Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Array Technologies, Nextracker, Sutro Biopharma - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal

Mar 16, 2025
pulisher
Mar 15, 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Bay Area biotech company once worth $2B guts staff, departing execs get $600K - MSN

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

Cattle Post Gains on Friday, Helped by Cah Strength - The Globe and Mail

Mar 14, 2025
pulisher
Mar 14, 2025

Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals

Mar 14, 2025
pulisher
Mar 14, 2025

Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro prioritizes preclinical ADC programs - BioWorld Online

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter

Mar 14, 2025
pulisher
Mar 14, 2025

This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review - BioSpace

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView

Mar 14, 2025

Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):